Fredun Pharmaceuticals Limited (BOM:539730)
India · Delayed Price · Currency is INR 1,473.70
-19.75 (-1.32%)
At close: Nov 6, 2026
Fredun Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 8,639 | 6,333 | 4,517 | 3,466 | 2,743 | 2,217 |
Other Revenue | 22.58 | 21.42 | 21.11 | 15.79 | 3.34 | 27.23 |
| 8,662 | 6,355 | 4,538 | 3,482 | 2,747 | 2,245 | |
Revenue Growth | 63.24% | 40.03% | 30.35% | 26.75% | 22.37% | 67.74% |
Cost of Revenue | 6,509 | 4,721 | 3,499 | 2,757 | 2,191 | 1,843 |
Gross Profit | 2,153 | 1,634 | 1,039 | 724.71 | 555.79 | 401.99 |
Selling, General & Admin | 727.99 | 725.01 | 514.61 | 344.89 | 278.02 | 252.54 |
Other Operating Expenses | 158.06 | - | -12.02 | -1.12 | -1.97 | 7.33 |
Operating Expenses | 1,010 | 807.47 | 552.99 | 381.73 | 304.14 | 284.58 |
Operating Income | 1,142 | 826.38 | 486.21 | 342.99 | 251.65 | 117.41 |
Interest Expense | -406.19 | -374.88 | -204.24 | -125.18 | -75.62 | -43.91 |
Interest & Investment Income | 6.6 | 6.6 | 2.67 | 0.14 | 0.23 | 0.06 |
Currency Exchange Gain (Loss) | 29.96 | 29.96 | 9.82 | 7.19 | 13.85 | 11.81 |
Other Non Operating Income (Expenses) | -18.1 | -18.1 | -19.53 | -10.62 | -15.94 | 0.64 |
EBT Excluding Unusual Items | 754.53 | 469.96 | 274.94 | 214.52 | 174.18 | 86 |
Pretax Income | 754.53 | 469.96 | 274.94 | 214.52 | 175.09 | 86 |
Income Tax Expense | 273.23 | 143.75 | 77.54 | 58.29 | 67.02 | 22.65 |
Net Income | 481.3 | 326.21 | 197.39 | 156.23 | 108.07 | 63.35 |
Net Income to Common | 481.3 | 326.21 | 197.39 | 156.23 | 108.07 | 63.35 |
Net Income Growth | 74.80% | 65.26% | 26.34% | 44.57% | 70.58% | 214.45% |
Shares Outstanding (Basic) | 16 | 15 | 14 | 14 | 13 | 12 |
Shares Outstanding (Diluted) | 17 | 16 | 14 | 14 | 13 | 12 |
Shares Change | 24.95% | 14.78% | - | 3.66% | 7.85% | 4.06% |
EPS (Basic) | 30.05 | 22.27 | 14.17 | 11.22 | 8.04 | 5.09 |
EPS (Diluted) | 27.66 | 20.41 | 14.17 | 11.22 | 8.04 | 5.09 |
EPS Growth | 39.90% | 43.98% | 26.34% | 39.48% | 58.14% | 202.19% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -787.85 | -616.89 | -227.04 | -80.78 | -239.03 | -66.66 |
Free Cash Flow Per Share | -45.27 | -38.59 | -16.30 | -5.80 | -17.79 | -5.35 |
Dividend Per Share | - | 0.233 | 0.233 | 0.233 | 0.233 | 0.233 |
Dividend Growth | - | 0% | 0% | 0% | 0% | 0% |
Gross Margin | 24.85% | 25.71% | 22.90% | 20.82% | 20.23% | 17.91% |
Operating Margin | 13.19% | 13.00% | 10.71% | 9.85% | 9.16% | 5.23% |
Profit Margin | 5.56% | 5.13% | 4.35% | 4.49% | 3.93% | 2.82% |
Free Cash Flow Margin | -9.10% | -9.71% | -5.00% | -2.32% | -8.70% | -2.97% |
EBITDA | 1,266 | 908.24 | 535.35 | 380.41 | 279.3 | 138.74 |
EBITDA Margin | 14.62% | 14.29% | 11.80% | 10.93% | 10.17% | 6.18% |
D&A For EBITDA | 123.69 | 81.87 | 49.14 | 37.42 | 27.65 | 21.33 |
EBIT | 1,142 | 826.38 | 486.21 | 342.99 | 251.65 | 117.41 |
EBIT Margin | 13.19% | 13.00% | 10.71% | 9.85% | 9.16% | 5.23% |
Effective Tax Rate | 36.21% | 30.59% | 28.20% | 27.17% | 38.28% | 26.33% |
Revenue as Reported | 8,699 | 6,391 | 4,563 | 3,491 | 2,765 | 2,261 |
Advertising Expenses | - | - | - | 11 | 0.99 | 4.58 |